I track my HRV, my glucose, my sleep architecture. I have a protocol for almost everything. But there is a category of health risk where individual optimization is completely useless: a bacterial infection that no available antibiotic can touch. You cannot biohack your way out of a carbapenem-resistant Klebsiella. Your Oura ring cannot help you.
The 2026 AMR Benchmark Report dropped yesterday, and the number that stopped me was 7. That is the total count of late-stage or recently approved antimicrobial products targeting the highest-priority resistant pathogens. For the entire planet. The report's co-author Martijn van Gerven called the pipeline situation "really bad," which is unusually blunt language for a policy document and is, if anything, an understatement.
The Pipeline Failure Has a Specific Address
This is where I want to be precise, because the biology gets blamed too often. Yes, bacteria evolve. That is not the crisis. The crisis is that we built a market structure where discovering new antibiotics is economically irrational. Antibiotics get prescribed for short courses, resistance emergence means they get used less over time to protect efficacy, and the development timeline runs 10 to 15 years. Venture capital does not love those numbers. The result: large pharmaceutical companies have largely exited the antibiotic space, leaving small biotechs to carry the load, and many of those fold before they reach approval.
The 2 new gonorrhea treatments approved recently, zoliflodacin and gepotidacin, are genuinely good news. They represent the first major advances in that treatment area in decades, arriving just as gonorrhea cases are rising and existing options are failing. But of the 25 pharmaceutical companies the report evaluated, only 2 had detailed plans to make their new drugs available and affordable in low- and middle-income countries. That means most of the innovation that does exist is being built for wealthy markets and will sit inaccessible to the populations facing the worst resistance burden. By 2050, projections put AMR deaths at 10 million per year, with 80% of those occurring in lower-income countries.
I will grant Dr. Alex Chen's likely objection here: better antibiotic stewardship and reducing over-the-counter antibiotic sales in low-regulation markets would reduce the resistance pressure substantially. He is right. But stewardship alone does not solve a pipeline that is contracting, and it does not explain why a child under 5 faces an 8-year delay before approved adult antibiotics get reformulated into pediatric doses. That is a pure investment prioritization failure, not a prescribing behavior problem.
Where Optimization Actually Lives in This Problem
The systems framing here matters. Drug-resistant infections are not getting harder to treat because microbes are unusually clever in 2026. They are getting harder to treat because the ROI on fighting them does not work under current incentive structures, diagnostic infrastructure in resource-limited settings is too weak to support targeted prescribing, and the small number of new drugs that do get approved lack access plans that would get them to high-burden populations.
The fix requires governments to directly fund antibiotic R&D as public infrastructure, the way they fund roads or power grids. Not tax incentives. Direct funding, with contractual access requirements built in from day one. The Access to Medicine Foundation's report makes clear that "until antibiotic discovery is funded at a scale that matches the threat posed by AMR, efforts will be reactive instead of proactive." Reactive medicine is expensive medicine. Anyone running a long-term health strategy, personal or national, knows the compounding cost of not addressing a slow-building risk early.
We have 7 products in the late-stage pipeline. That number needs to be 70, with access plans attached to every one of them. The bacteria are not waiting on the meta-analysis.
